Abstract 327TiP
Background
Management of platinum resistant ovarian cancer has always been challenging for oncologists. Best option in this setting is single agent chemotherapy with bevacizumab. However, due to various contraindications and financial constraints, many of them do not receive bevacizumab. Due to high expression of folate receptor alpha in high grade epithelial ovarian cancers pemetrexed could be a potential treatment option. To our knowledge there are only 2 phase II trials across the globe showing the effectiveness of pemetrexed in platinum resistant/refractory ovarian cancer and till date there is no prospective data in Indian patients with platinum resistant/refractory ovarian cancer.
Trial design
The study is a single centre, investigator-initiated, single arm phase II clinical trial designed using Simon two stage optimal design. Eligible patients are adults (age ≥18 years), with histologically confirmed high grade epithelial ovarian or primary peritoneal cancer, who have relapsed within 6 months of platinum-based chemotherapy, who are bevacizumab ineligible, with ECOG performance status of 0-2, adequate organ function, with either measurable disease with at least one target lesion for response evaluation as per RECIST 1.1 criteria or non-measurable disease with CA-125 level ≥2 times ULN measured at least 2 weeks before enrolment. Estimated sample size is 63. At least 2 out of 22 responses in stage I are expected in order to proceed to stage II and further recruitment of the patients. Baseline contrast enhanced CT scan of chest, abdomen and pelvis along with CA-125 level will be recorded. Eligible patients will receive Pemetrexed at dose of 500 mg/m2 every 21 days. Response assessment will be done after 3 cycles of chemotherapy (RECIST 1.1 will be used for measurable disease and GCIG criteria using CA-125 level will be used for non-measurable disease) and subsequent responses will be assessed every 12-16 weeks. Treatment will continue until progression, intolerable toxicity or death. Primary objective is Objective Response Rate (ORR). Secondary objectives are Progression Free survival (PFS), Overall Survival (OS), Clinical Benefit Rate (CBR), Toxicity profile and Quality of Life (QoL).
Clinical trial identification
CTRI/2022/08/044939.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract